ClinicalTrials.gg
TerminatedNCT06149455Updated Nov 12, 2026Results posted

Preoperative Prophylactic Antibiotic Duration in Moderate to High Risk Ureteroscopy

A Phase 4 interventional study of Duration of antibiotics in Infections, Urinary Tract and Nephrolithiasis, sponsored by University of California, San Francisco. Terminated at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Principal investigator and other key study team members departed the original institution and lack local support for study completion. Therefore, decision was made not to continue the study.
Updated Nov 12, 2026Now TerminatedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.

Enrollment
161st of 225
34 · median 100
Started
2024
with 16 others
Phase 4
40 of 275
10 open now
Registered
223rd of 275
by date
Lead sponsor
6 of 275
University of California, San Francisco

Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 161st largest by enrollment of the 225 interventional ones that give a count, is one of 17 that started in 2024, is one of 40 in phase 4, and was the 223rd registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Urinary Tract Infections with a site in United States, or all of them as a file.
02

Study summary

The goal of this non-inferiority randomized controlled trial: is to test the hypothesis that the that there is no additional benefit from a longer course (7 days) versus a shorter course (2 days) of pre-operative antibiotics in patients with moderate to high risk of infection undergoing ureteroscopy. The main questions it aims to answer are:

  1. Determine the safety and efficacy of a short course (2 days) as compared to a long course (7 days)
  2. Identify secondary predictors of post-operative infectious complications
Read the detailed description

Post-operative infectious complications including urinary tract infection (UTI), systemic inflammatory response syndrome (SIRS), and sepsis are uncommon but potentially devastating complications after ureteroscopy. The clinical guidance from the American Urologic Association (AUA) and the European Association of Urology (EAU) is to provide treatment for symptomatic urinary tract infections however the management for asymptomatic patients with positive cultures or those patients who are otherwise at high risk of urinary tract colonization is unclear. As a result, there is significant practice variation in pre-operative prophylactic antibiotic prescription, even amongst fellowship trained endourologists, with some providers prescribing over ten days of pre-operative antibiotics while others offer none. This is a critical gap in our understanding of pre-operative prophylactic antibiotic utilization in a population of patients not only at higher risk of harboring multi-drug resistant (MDR) organisms but are also more susceptible to deleterious outcomes due to their frailty. Recent randomized trials have demonstrated that short courses of pre-operative antibiotics are no less protective than long courses in patients undergoing percutaneous nephrolithotomy (PCNL) for stone removal. Ureteroscopy is the most commonly performed stone surgery worldwide. Establishing an evidence-based approach for antibiotic prophylaxis in the ureteroscopic surgical patient population will be impactful for a large number of patients. The goal of this study is to implement a well-designed randomized clinical trial to establish the standardized antibiotic protocol necessary to minimize unnecessary antibiotic use which may otherwise lead to adverse reactions and proliferation of multi-drug resistant organisms.

03

Conditions studied

  • Infections, Urinary Tract
  • Nephrolithiasis
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age (greater than or equal to 18 years)
  • indwelling ureteral stent in place
  • nephrostomy tube in place
  • indwelling foley catheter, suprapubic catheter or clean intermittent catheterization
  • asymptomatic bacteriuria
  • bowel interposition (such as ileal conduit, neobladder)
  • (such as for transplant recipients, active chemotherapy use)

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • active infection
  • received antibiotics within 7 days preceding surgery that were not prescribed for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Short duration of preoperative antibiotics (2 days)

    Drug: Duration of antibiotics

  • Active comparator
    Long duration of preoperative antibiotics (7 days)

    Drug: Duration of antibiotics

Interventions

  • DrugDuration of antibiotics

    Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.

06

What researchers measure

Primary outcomes

  1. Infectious Complication Rate

    any occurrence of urinary tract infection, pyelonephritis, systemic inflammatory response syndrome or sepsis

    Time frame: 30 days after surgery

Secondary outcomes

  1. Non-infectious Complications Including Readmission

    Any other complications after the surgical procedure such as pain, readmission, urinary retention, etc

    Time frame: 30 days after surgery

  2. Adverse Reaction to Antibiotic Regimen

    Any adverse reaction to antibiotic regimen

    Time frame: 2-7 days prior to surgery (depending on which arm the patient was randomized to)

07

Results

Posted Nov 12, 2026
Limitations and caveats
We were ultimately unable to complete the proposed trial given significant changes in the study team availability.

Participant flow

Participant flow — Overall Study
MilestoneShort Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)
Started1816
Completed1816
Not completed00

Outcome measures

PrimaryInfectious Complication Rate

any occurrence of urinary tract infection, pyelonephritis, systemic inflammatory response syndrome or sepsis

Time frame:
30 days after surgery
Reported as:
Count of participants · Participants
Infectious Complication Rate
ParticipantsShort Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)
Infectious complication occurence11
infectious complication did not occur1715
SecondaryNon-infectious Complications Including Readmission

Any other complications after the surgical procedure such as pain, readmission, urinary retention, etc

Time frame:
30 days after surgery
Reported as:
Count of participants · Participants
Non-infectious Complications Including Readmission
ParticipantsShort Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)
Non-infectious complication did occur53
Non-infectious complication did not occur1313
SecondaryAdverse Reaction to Antibiotic Regimen

Any adverse reaction to antibiotic regimen

Time frame:
2-7 days prior to surgery (depending on which arm the patient was randomized to)
Reported as:
Count of participants · Participants
Adverse Reaction to Antibiotic Regimen
ParticipantsShort Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)
Adverse reaction to antibiotic occurred00
Adverse reaction to antibiotic did not occur1816

Adverse events

Collected over From enrollment until end of follow up, up to 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Short Duration of Preoperative Antibiotics (2 Days)0/18 (0%)1/18 (5.6%)5/18 (27.8%)
Long Duration of Preoperative Antibiotics (7 Days)0/16 (0%)0/16 (0%)4/16 (25%)
Most frequent serious events
Most frequent serious events
EventShort Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)
Postoperative sepsis requiring ICU admissionRenal and urinary disorders1/180/16
Most frequent other events
Most frequent other events
EventShort Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)
Postoperative pain or lower urinary tract symptoms requiring evaluation in emergency departmentInjury, poisoning and procedural complications5/183/16
Urinary tract infectionRenal and urinary disorders0/181/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Short Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)Total
Median61 (47 to 65)60 (46 to 68)60 (46 to 68)
Sex: Female, Male
Sex: Female, Male(Participants)Short Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)Total
Female71017
Male11617
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Short Duration of Preoperative Antibiotics (2 Days)Long Duration of Preoperative Antibiotics (7 Days)Total
American Indian or Alaska Native000
Asian6410
Native Hawaiian or Other Pacific Islander000
Black or African American000
White111223
More than one race000
Unknown or Not Reported101
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We have no plans to make individual participant data available to other researchers.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in Jul 2025, 18 months.

Results were first posted in Nov 2026, 1 year 4 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2026 → Jul 2025 and completion Jan 2026 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2023
First posted
Nov 29, 2023
StartActual
Jan 1, 2024
Primary completionActual
Jul 1, 2025was Jan 2026
CompletionActual
Jul 1, 2025was Jan 2026
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Terminated Principal investigator and other key study team members departed the original institution and lack local support for study completion. Therefore, decision was made not to continue the study.
changed Nov 12, 2026
Results
Results posted
posted Nov 12, 2026
Primary completion
Jan 1, 2026→Jul 1, 2025 (actual)
Nov 12, 2026
Study completion
Jan 1, 2026→Jul 1, 2025 (actual)
Nov 12, 2026
Enrollment
72 (estimated)→34 (actual)
Nov 12, 2026
Interventions
Added Drug: Duration of antibiotics; removed Duration of antibiotics
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Editedinfectious complication rateInfectious Complication RateTime frame: 30 days after surgery
Nov 12, 2026
Documents
Secondary outcomes
2 edited, 1 removed
What changed in the outcomes
  • EditedNon-infectious complications including readmissionComplications Including ReadmissionTime frame: 30 days after surgery
  • EditedAdverse reactionReaction to antibiotic regimenAntibiotic RegimenTime frame: 2-7 days prior to surgery (depending on which arm the patient was randomized to)
  • RemovedIdentification of secondary markers of post-operative sepsisTime frame: Obtained during the peri-operative period
Nov 12, 2026
Design
Not applicable→Phase 4
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Terminated
    Why stopped Principal investigator and other key study team members departed the original institution and lack local support for study completion. Therefore, decision was made not to continue the study.
    Results posted
    Primary completion Jan 1, 2026→Jul 1, 2025 (now actual)
    Study completion Jan 1, 2026→Jul 1, 2025 (now actual)
    Enrollment 72 (estimated)→34 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • Editedinfectious complication rateInfectious Complication RateTime frame: 30 days after surgery
    Secondary outcomes 2 edited, 1 removed
    What changed in the outcomes
    • EditedNon-infectious complications including readmissionComplications Including ReadmissionTime frame: 30 days after surgery
    • EditedAdverse reactionReaction to antibiotic regimenAntibiotic RegimenTime frame: 2-7 days prior to surgery (depending on which arm the patient was randomized to)
    • RemovedIdentification of secondary markers of post-operative sepsisTime frame: Obtained during the peri-operative period
    Interventions Added Drug: Duration of antibiotics; removed Duration of antibiotics
    Design Not applicable→Phase 4
    + 3 other changes: verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06149455
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
Jan 1, 2024
Primary completion
Jul 1, 2025
Completion
Jul 1, 2025
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Thomas Chi, MD, MBA
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion